Tactile Systems Technology stock, medical devices

Tactile Systems Technology stock falls 1.19 percent on Q2 update

Published on 09/23/2026 at 21:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Tactile Systems Technology stock faces a revised 2026 revenue outlook after Q2 revenue reached USD 85.7 million. EPS was USD 0.34 versus USD 0.14 consensus.

Tactile Systems Technology stock, medical devices, Q2 2026 results, revenue guidance, Nasdaq, Illustration mit AI erstellt.

Tactile Systems Technology stock (ISIN US87357P1003) was trading at USD 22.41 on Nasdaq on September 23, 2026, down 1.19 percent from the previous close. The medical-device company delivered USD 85.7 million in second-quarter 2026 revenue, while its updated full-year outlook highlights a split between lymphedema growth and airway-clearance pressures.

Q2 revenue reaches USD 85.7 million

MarketBeat reported that Tactile Systems posted second-quarter 2026 EPS of USD 0.34 against a USD 0.14 consensus estimate, while revenue reached USD 85.7 million. The earnings gap is the sharper signal: EPS exceeded consensus by USD 0.20, whereas revenue was described as broadly in line with expectations.

The latest quarter also marked a clear operating contrast. Lymphedema revenue rose 12 percent year over year to USD 73.6 million, while AffloVest revenue fell 7 percent to USD 12.1 million, according to the Q2 earnings transcript summarized by Globe and Mail. The product mix matters because lymphedema growth currently offsets a temporary inventory effect in airway clearance.

Guidance reflects a product split

For fiscal 2026, management expects total revenue of USD 360 million to USD 366 million, representing growth of 9 percent to 11 percent year over year, Globe and Mail reported on the Q2 call. The company expects lymphedema revenue to grow in the low double digits, while airway-clearance revenue is projected to remain close to flat.

The guidance frames the investment case around execution rather than a single headline number. Tactile Systems is managing inventory patterns among several durable medical equipment partners during the next-generation AffloVest launch, while its core lymphedema business continues to expand. The company also expects adjusted EBITDA of USD 49 million to USD 51 million for fiscal 2026.

Stock trades below its yearly high

Tactile Systems Technology had a market capitalization of USD 505,486,683 on September 23, 2026. Its 52-week range was USD 13.38 to USD 37.77, placing the current price USD 15.36 below the high and USD 9.03 above the low. The market snapshot puts the quarterly results in perspective: operational growth is visible, but the share price remains materially below its yearly peak.

At the September 23, 2026 Nasdaq session, Tactile Systems Technology stock stood at USD 22.41 at 3:41 p.m. ET. The daily move was negative even as second-quarter EPS exceeded consensus, leaving guidance execution and the AffloVest inventory normalization as the main measurable checkpoints.